Ramipril vs lisinopril efficacy
Pro Research Analysisby 
Searched over 200M research papers
Ramipril vs Lisinopril Efficacy in Hypertension Treatment
A randomized, double-blind multicenter trial compared ramipril and lisinopril in patients with mild to moderate hypertension. Ramipril 2.5 mg daily resulted in a higher response rate (67%) than lisinopril 10 mg daily (49%), with a statistically significant difference. The reduction in blood pressure was also slightly greater with ramipril (27/15 mm Hg) compared to lisinopril (23/11 mm Hg). Additionally, ramipril was better tolerated, with fewer adverse events reported than with lisinopril 10 mg daily. Lisinopril 5 mg daily was not clinically effective in this study group.
Comparative Effectiveness in Heart Failure with Reduced Ejection Fraction (HFrEF)
A large cohort study matched patients with HFrEF treated with enalapril, lisinopril, or ramipril. When given at equivalent doses, there was no significant difference in all-cause mortality between ramipril and lisinopril. The study concluded that these ACE inhibitors are equally effective for HFrEF when dosed appropriately, and the choice between them does not impact mortality outcomes.
Efficacy in Post-Acute Myocardial Infarction with Metabolic Syndrome
A pooled analysis of four randomized studies in post-acute myocardial infarction patients with or without metabolic syndrome found that lisinopril and zofenopril significantly reduced the 1-year risk of major cardiovascular events compared to placebo, while ramipril did not show a significant benefit over placebo. Lisinopril’s efficacy was similar to zofenopril and superior to ramipril in this contextBorghi2017Degli2017.
Effects on Endothelial Progenitor Cell (EPC) Migration
Laboratory studies on coronary artery disease patients showed that both ramipril and lisinopril increased EPC migration, which is beneficial for vascular repair. At high doses, lisinopril had a greater effect on EPC migration than ramipril, suggesting a potential advantage for lisinopril in promoting vascular health at higher doses. However, at lower and medium doses, the difference between the two drugs was less pronouncedOktaviono2021Achmad2023.
Organ-Specific ACE Inhibition and Pharmacological Profiles
Preclinical studies in hypertensive rats demonstrated that both ramipril and lisinopril provide strong and long-lasting inhibition of ACE in the aorta and lung, correlating with their antihypertensive effects. However, differences were observed in other organs: lisinopril had a longer-lasting effect in the brain, while ramipril’s effect was weaker in the kidney compared to some other ACE inhibitors. These differences may influence drug selection in patients with specific organ concernsCushman1989Cushman1989.
Clinical Practice and Prescription Patterns
Real-world data indicate that physicians are less likely to prescribe target doses of lisinopril (which has a higher numerical target dose) compared to ramipril, potentially due to psychological biases related to dose numbers. Achieving target doses of either drug is associated with better outcomes in heart failure patients, emphasizing the importance of dose optimization regardless of the specific ACE inhibitor used.
Conclusion
In summary, ramipril may offer slightly better efficacy and tolerability than lisinopril for mild to moderate hypertension, while both drugs are equally effective for heart failure when dosed equivalently. Lisinopril may have an advantage in post-myocardial infarction patients with metabolic syndrome and in promoting EPC migration at higher doses. Organ-specific effects and prescription patterns may also influence the choice between these two ACE inhibitors, but both remain effective options in cardiovascular disease managementKoenig1992Fröhlich2018Oktaviono2021+6 MORE.
Sources and full results
Most relevant research papers on this topic